Hypereosinophilic Syndrome (HES) Cell Models for Research

Hypereosinophilic syndrome (HES) is a rare hematologic disorder characterized by persistent eosinophilia (absolute eosinophil count >1.5 x 10^9/L) with end-organ damage, most commonly involving the skin, heart, lungs, and nervous system. According to the World Health Organization (WHO) 2022 classification, HES is a subtype of myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions. The global incidence is estimated at 0.5-1 per 100,000 individuals per year, with a prevalence of approximately 1-5 per 100,000. The disease affects adults predominantly, with a median age at diagnosis of 40-50 years, and shows a slight male predominance. Key risk factors include genetic predisposition, particularly mutations in PDGFRA, PDGFRB, FGFR1, and JAK2, as well as underlying lymphoproliferative disorders. The 5-year overall survival for HES varies by subtype: for PDGFRA-associated HES, survival exceeds 80% with imatinib therapy; for lymphocytic HES, 5-year survival is approximately 70-80%; for idiopathic HES, survival ranges from 60-80% depending on organ involvement. Cardiac involvement (endomyocardial fibrosis) remains a major cause of morbidity and mortality, with a 5-year survival of 50-70% in untreated cases. The National Cancer Institute (NCI) reports that HES-related mortality is primarily due to heart failure, thromboembolism, and progression to acute myeloid leukemia (AML) in a subset of patients.

HES serves as an excellent model for studying eosinophil biology, tyrosine kinase signaling, and targeted therapy resistance. The disease is genetically heterogeneous, with well-defined subtypes: myeloproliferative HES (associated with FIP1L1-PDGFRA fusion), lymphocytic HES (clonal T-cell populations producing IL-5), and idiopathic HES. Public datasets such as TCGA, cBioPortal, and GEO provide genomic and transcriptomic data for HES and related eosinophilic neoplasms. Open questions include the mechanisms of imatinib resistance, the role of the bone marrow microenvironment, and the identification of novel therapeutic targets for corticosteroid-resistant HES. The rarity of HES makes gene-edited cell models particularly valuable for functional studies, as they allow precise dissection of mutation-specific phenotypes and drug responses.

HES pathogenesis is driven by constitutive activation of tyrosine kinase signaling pathways, often due to gene fusions or mutations. Key pathways include:

• • PDGFRA/PDGFRB signaling:
• • FIP1L1-PDGFRA fusion leads to constitutive PDGFRA kinase activity.
• • ETV6-PDGFRB fusion activates PDGFRB in a ligand-independent manner.
• • Downstream effectors: PI3K/AKT, MAPK/ERK, JAK/STAT.
• • JAK/STAT pathway:
• • Activating mutations in JAK2 (e.g., V617F) or fusions involving JAK2 (e.g., PCM1-JAK2) drive eosinophil proliferation.
• • STAT3 and STAT5 are frequently phosphorylated in HES.
• • IL-5 signaling:
• • In lymphocytic HES, clonal T cells produce IL-5, stimulating eosinophil production via IL-5Rα and JAK2/STAT5.
• • Epigenetic dysregulation:
• • Mutations in ASXL1, TET2, and EZH2 are observed in some HES cases and may contribute to clonal evolution.

Data sources: COSMIC (v97), ClinVar, and published HES cohorts. Frequencies are approximate and vary by subtype.

Key signaling nodes and networks in HES:

• • PI3K/AKT/mTOR pathway:
• • Activated by PDGFRA/PDGFRB fusions and JAK2 mutations.
• • Promotes cell survival, proliferation, and metabolism.
• • mTOR inhibitors (e.g., rapamycin) show preclinical efficacy.
• • MAPK/ERK pathway:
• • Downstream of activated tyrosine kinases.
• • Drives proliferation and cytokine production.
• • MEK inhibitors are being explored in imatinib-resistant HES.
• • JAK/STAT pathway:
• • Central to IL-5 signaling and JAK2 fusion-driven HES.
• • STAT3 and STAT5 activate target genes involved in eosinophil differentiation (e.g., GATA1, CEBPA).
• • NF-κB pathway:
• • Activated in lymphocytic HES; contributes to cytokine release and inflammation.
• • Epigenetic regulators:
• • ASXL1, TET2, and EZH2 mutations alter chromatin states, affecting gene expression and clonal evolution.

Organoid advantages: Patient-derived organoids from HES patients can recapitulate disease heterogeneity and drug responses. However, eosinophil organoids are challenging due to short lifespan; iPSC-derived eosinophil models are emerging as alternatives.

Note: EOL-1 is the most widely used HES cell line, harboring the FIP1L1-PDGFRA fusion, and is sensitive to imatinib. It is available from commercial sources (e.g., DSMZ, ATCC) but company names are not mentioned per guidelines.

Animal models for HES include:

• • Genetically engineered mouse models (GEMMs):
• • FIP1L1-PDGFRA knock-in mice develop eosinophilia and cardiac involvement.
• • IL-5 transgenic mice exhibit eosinophilia but lack end-organ damage.
• • JAK2 V617F knock-in mice show myeloproliferative features with eosinophilia.
• • Patient-derived xenograft (PDX) models:
• • Limited due to the rarity of HES and the difficulty of engrafting human eosinophil progenitors in mice.
• • Humanized mice reconstituted with HES patient hematopoietic stem cells can model disease.
• • Induced models:
• • Administration of IL-5 or GM-CSF to mice induces eosinophilia.
• • These models are useful for testing anti-eosinophil therapies but do not fully recapitulate genetic subtypes.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines that precisely model HES-associated mutations. Examples include:

• • FIP1L1-PDGFRA knock-in in EOL-1 or HL-60 cells: Introduces the fusion gene to study imatinib sensitivity and resistance mechanisms.
• • PDGFRA knockout in eosinophilic cell lines: Validates the dependency on PDGFRA signaling.
• • JAK2 V617F knock-in in hematopoietic cell lines: Models JAK2-mutant HES and tests JAK inhibitors.
• • IL-5Rα knockout in eosinophil progenitors: Dissects IL-5 signaling in lymphocytic HES.

Commercially available, sequence-verified gene-edited cell models (e.g., PDGFRB mutant knock-in lines, ASXL1 knockout lines) accelerate research by providing reproducible, validated tools. These models are generated using CRISPR, TALEN, or base editing technologies and are quality-controlled for off-target effects and genomic stability. They enable functional genomics, drug screening, and target validation in a disease-relevant context.

Gene-edited cell models allow systematic interrogation of gene function in HES. For example:

• • Knockout of FIP1L1-PDGFRA in EOL-1 cells abolishes imatinib sensitivity, confirming the fusion as the primary driver.
• • Knock-in of JAK2 V617F in myeloid cell lines induces eosinophilic differentiation and cytokine independence.
• • CRISPR screens in eosinophilic cell lines identify synthetic lethal partners with PDGFRA, such as PI3K or mTOR components.

These models help validate candidate genes from genomic studies (e.g., TCGA, COSMIC) and prioritize targets for drug development.

Isogenic pairs (e.g., wild-type vs. FIP1L1-PDGFRA knock-in) are powerful for drug screening. Applications include:

• • High-throughput screening of small molecule libraries to identify compounds that selectively kill mutant cells.
• • Modeling imatinib resistance by introducing secondary mutations (e.g., PDGFRA T674I) using CRISPR knock-in.
• • Testing combination therapies (e.g., imatinib + JAK inhibitors) in isogenic backgrounds.

Resistance modeling with gene-edited cells can reveal bypass signaling pathways and inform rational combination strategies.

CRISPR synthetic lethality screens in HES cell models can identify biomarkers of drug response. For example:

• • Genome-wide knockout screens in FIP1L1-PDGFRA-positive cells treated with imatinib can reveal genes whose loss sensitizes or confers resistance.
• • Transcriptomic profiling of isogenic lines can identify gene expression signatures predictive of response to targeted therapies.
• • Epigenetic CRISPR screens (e.g., CRISPRi/CRISPRa) can uncover regulators of eosinophil differentiation and survival.

These approaches accelerate biomarker discovery for patient stratification and precision medicine in HES.